Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises bioMérieux on AviaraDx Acquisition


SAN FRANCISCO, CA, September 18, 2008 — BioMérieux announced that it has signed an agreement to acquire privately held AviaraDx, Inc. for $60 million. BioMérieux plans to keep AviaraDx as an independent legal entity called bioTheranostics, Inc. Covington & Burling LLP advised bioMérieux on the transaction.

BioMérieux, based in France, specializes in the in vitro diagnostics sector, and designs, develops, produces and markets diagnosis systems for medical or industrial applications. AviaraDX is a molecular in vitro diagnostics company based in San Diego, California. The acquisition of AviaraDx’s proprietary molecular cancer tests enables bioMérieux to offer valuable diagnostic tools for cancer management and assist oncologists in making critical clinical and therapeutic decisions.

The Covington corporate team was led by partner Bruce Deming and associate Ingrid Rechtin, both resident in the firm’s San Francisco office. The Covington team also included Washington-based partner Michael Francese and associate Mary DeYoung (benefits), and partner Robert Heller (tax).

Share this article: